Ian M. Waxman

1 ta ish

Bristol-Myers Squibb (Belgium)

1. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

   Robert J. Motzer, Bernard Escudier, Ray McDermott +24

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.679071